

Correction

Ueki K, Sasako T, Kato M, *et al.* Design of and rationale for the Japan Diabetes Optimal Integrated Treatment study for 3 major risk factors of cardiovascular diseases (J-DOIT3): a multicenter, open-label, randomized, parallel-group trial. *BMJ Open Diabetes Research and Care* 2016;4:e000123. doi:10.1136/bmjdr-2015-000123corr1

The contributors statement has been updated to read: YaO designed the protocol and steered the study as a biostatistician.

The competing interests statement has been updated to read: YuO reports lecture fees from Nippon Boehringer Ingelheim, and Takeda. YaO reports lecture fees from Eli Lilly, Novo Nordisk, Sanofi, and Takeda; consulting fees from Astellas, Chugai Pharmaceutical Co, Ltd, and Kowa; being the chairman of the board of directors, and owning stock in Statcom Co, Ltd. MN reports lecture fees from AbbVie G. K., Astellas, Daiichi Sankyo, Eli Lilly, Kissei, Kowa, Kyowa Hakko Kirin, Meiji Seika Pharma Co, Ltd, Mitsubishi Tanabe, MSD, Novo Nordisk, Sanofi, Ono, Taisho Toyama, and Takeda; grants and endowments from AstraZeneca, Daiichi Sankyo, Kowa, Kyowa Hakko Kirin, Mitsubishi Tanabe, Mochida Pharmaceutical Co, Ltd, Sanwa Kagaku, and Takeda.

Affiliation number 14 has also been added for Mitsuhiko Noda. Affiliation 14: Department of Endocrinology and Diabetes, Saitama Medical University, Saitama, Japan.

BMJ Open Diabetes Research and Care 2016;4:e000123. doi:10.1136/bmjdr-2015-000123corr1



CrossMark